The use of aspirin in polycythaemia vera and primary thrombocythaemia

Blood Reviews

Volumn 12, Issue 1, 1998, Pages 12-22

  Willoughby, S ^a   Pearson, T C ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOXANE A2; TICLOPIDINE;

ARACHIDONIC ACID METABOLISM; BLEEDING; BLOOD VESSEL OCCLUSION; BRONCHOSPASM; HUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS;

EID: 0031902866     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(98)90026-1     Document Type: Article

References (86)

1. Chievitz E, Thiede T. Complications and causes of death in polycythaemia. Acta Med Scand 1962; 172: 513-523.
2. Cortelazzo S, Finazzi G, Ruggeri M et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 1132-1136.
3. van Genderen PJJ, Mulder PGH, Waleboer M, vandeMoesdijk D, Michiels JJ. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol 1997; 97: 179-184.
4. Barabas AP, Offen DN, Meinhard EA. The arterial complications of polycythaemia vera. Br J Surg 1973; 60: 183-187.
5. Messinezy M, Pearson TC, Prochazka A, Wetherley-Mein G. Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: retrospective study from one centre. Br J Haematol 1985; 61: 657-666.
6. Murphy S, Hand H, Rosenthal D, Lazzlo J. Essential thrombocythemia: An interim report from the Polycythemia Vera Study Group. Semin Hematol 1986; 23: 177-182.
7. Pearson TC. Primary thrombocythaemia: diagnosis and management. Br J Haematol 1991; 78: 145-148.
8. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656-664.
9. Barbui T, Finazzi G, Dupuy E, Kiladjian J-J, Briere J. Treatment strategies in essential thrombocythaemia. Leukemia and Lymphoma 1996; 22 (Suppl 1) 149-160.
10. Pearson TC, Wetherley-Mein G. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet 1978; 2: 1219-1222.
11. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8: 556-562.
12. Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocytheraia. A retrospective study of 103 patients. Cancer 1991; 67: 2926-2930.
13. Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64: 1-12.
14. Michiels PJJ, van Genderen PJJ, Jansen PHP, Koudstaal PJ. Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders. Leukemia and Lymphoma 1996; 22 (Suppl 1): 65-70.
15. Pearson TC, Barbui T. The management of polycythemia vera. Hematology 1997; 2: 55-64.
16. Vadher BD, Machin SJ, Patterson KG, Sukhu C, Walker H. Life-threatening thrombotic and haemorrhagic problems associated with silent myeloproliferative disorders. Br J Haematol 1993; 85: 213-216.
17. Pearson TC, Wetherley-Mein G. The course and complications of idiopathic erythrocytosis. J Clin Lab Haematol 1979; 1: 189-196.
18. Pearson TC, Messinezy M. Polycythaemia and thrombocythaemia in the elderly. Baillières Clin Haematol 1987; 1: 355-387.
19. van Genderen PJ, Michiels JJ. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Presse Med 1994; 23: 73-77.
20. Michiels JJ. The myeloproliferative disorders: an historical appraisal and personal experiences. Leukemia and Lymphoma 1996; 22 (Suppl 1): 1-14.
21. Michiels JJ, Koudstaal PJ, Mulder AH, van Vliet HH. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 1993; 43: 1107-1110.
22. Michiels JJ, van Genderen PJ, van Vliet HH. Erythromelalgia and arterial thrombophilia in thrombocythemia. Ann N Y Acad Sci 1994; 714: 318-321.
23. Michiels JJ, van Genderen PJJ, Lindermans J, van Vliet HHDM. Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. Leukemia and Lymphoma 1996; 22 (Suppl 1): 47-56.
24. Michiels JJ, Abels J, Steketee J, van Vliet HH, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 1985; 102: 466-471.
25. Koudstaal PJ, Koudstaal A. Neurologic and visual symptoms in essential thrombocythaemia: efficacy of low-dose aspirin. Semin Thromb Hemost 1997; 23: 365-370.
26. Gunz FW. Haemorrhagic thrombocythemia: a critical review. Blood 1960; 15: 706-723.
27. Wasserman LR, Gilbert HS. Surgery in polycythemia vera. N Engl J Med 1963; 269: 1226-1230.
28. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-617.
29. Boughton BJ, Corbett WE, Ginsburg AD. Myeloproliferative disorders: a paradox of in-vivo and in-vitro platelet function. J Clin Pathol 1977; 30: 228-234.
30. Michiels JJ, ten Kate FW, Vuzevski VD, Abels J. Histopathology of erythromelalgia in thrombocythaemia. Histopathology 1984; 8: 669-678.
31. van Genderen PJJ, Michiels JJ. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 1997; 23: 357-363.
32. Pearson TC. Haemo-rheological considerations in the pathogenesis of vascular occlusive events in polycythaemia vera. Semin Thromb Hemost 1997; 23: 433-439.
33. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294.
34. Preston FE, Greaves M. Platelet suppressive therapy in clinical medicine. B J Haem 1985; 60: 589-597.
35. 2. Scandinavian Journal of Clinical & Laboratory Investigation (Supplement) 1990; 201: 103-108.
36. 2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137-1141.
37. Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G. Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. Chest 1995; 108 (4 Suppl): 247S-257S.
38. van Pampus EC, Huijgens PC, Zevenbergen A, Twaalfhoven H, van Kamp GJ, Langenhuijsen MM. Influence of aspirin on human megakaryocyte prostaglandin synthesis. Eur J Haematol 1993; 50: 264-268.
39. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
40. UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. BMJ 1988; 296: 316-320.
41. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-1581.
42. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308: 235-246.
43. Tartaglia AP, Goldberg JD, Berk PD, Wasserman LR. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 1986; 23: 172-176.
44. Landolfi R, Patrono C. Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. Leukemia and Lymphoma 1996; 22 (Suppl 1): 83-86.
45. Preston FE, Martin JF, Stewart RM, Davies-Jones GA. Thrombocytosis, circulating platelet aggregates, and neurological dysfunction. BMJ 1979; 2: 1561-1563.
46. Preston FE. Aspirin, prostaglandins, and peripheral gangrene. Am J Med 1983; 74: 55-60.
47. Landolfi R, Ciabattoni G, Patrignani P et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992; 80: 1965-1971.
48. Rocca B, Ciabattoni G, Tartaglione R et al. Increased thromboxane biosynthesis in essential thrombocythemia. Throm Haemost 1995; 74: 1225-1230.
49. van Genderen PJ, Michiels JJ, van Strik R, Lindemans J, van Vliet HH. Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thromb Haemost 1995; 73: 210-214.
50. Ginsberg MH, Frelinger AL, Lam SC et al. Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies. Blood 1990; 76: 2017-2023.
51. Abrams CS, Ellison N, Budzynski, AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990; 75: 128-138.
52. Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemost 1991; 65: 467-473.
53. Gralnick HR, Williams SB, McKeown L et al. Endogenous platelet fibrinogen: its modulation after surface expression is related to size-selective access to and conformational changes in the bound fibrinogen. Br J Haematol 1992; 80: 347-357.
54. Janes SL, Wilson DJ, Chronos N, Goodall AH. Evaluation of whole blood flow cytometric detection of platelet bound fibrinogen on normal subjects and patients with activated platelets. Thromb Haemost 1993; 70: 659-666.
55. Nurden P, Bilnour C, Smith M, Raymond JM, Nurden AT. Platelet activation and thrombosis: studies in a patient with essential thrombocythaemia. Am J Hematol 1996; 51: 79-84.
56. 2 are involved in the pathogenesis of erythromelalgia in thrombocythaemia. Mediators of Inflammation 1993; 2: 385-389.
57. Beard J, Hillmen P, Anderson CC, Lewis SM, Pearson TC. Primary thrombocythaemia in pregnancy. Br J Haematol 1991; 77: 371-374.
58. Radaelli F, Colombi M, Maiolo AT. Essential thrombocythemia in pregnancy: report of four cases. Hematologica 1994; 79: 360-363.
59. Griesshammer M, Heimpel H, Pearson TC. Essential thrombocythemia and pregnancy. Leukemia and Lymphoma 1996; 22 (Suppl 1): 57-64.
60. Pagliaro P, Arrigoni L, Muggiasca ML, Poggio M, Russo U, Rossi E. Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases. Am J Hematol 1996; 53: 6-10.
61. Willoughby SJB, Fairhead S, Woodcock BE, Pearson TC. Postpartum thrombosis in primary thrombocythaemia. Eur J Haematol 1997; 59: 121-123.
62. Budde U, Schaefer G, Mueller N et al. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984; 64: 981-985.
63. Fabris F, Casonato A, Grazia del Ben M, De Marco L, Girolami A. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br J Haematol 1986; 63: 75-83.
64. van Genderen PJJ, Leenknegt H, Michiels JJ, Budde Y. Acquired von Willebrand disease in myeloproliferative disorders. Leukemia and Lymphoma 1996; 22 (Suppl 1): 79-82.
65. Finazzi G, Budde U, Michiels JJ. Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes. Leukemia and Lymphoma 1996; 22 (Suppl 1): 71-78.
66. Budde U, Scharf RE, Franke P et al. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood 1993; 82: 1749-1757.
67. van Genderen PJ, Budde U, Michiels JJ, van Strik R, van Vliet HH. The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol 1996; 93: 962-965.
68. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413-1416.
69. Lanza FL, Royer GL, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980; 303: 136-138.
70. Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med 1986; 104: 390-398.
71. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-830.
72. Gruppo Italiano Studio Policitemia (GISP). Low-dose aspirin in polycythaemia vera: a pilot study. B J Haem 1997; 97: 453-456.
73. Picado C, Castillo JA, Montserrat JM, Agusti-Vidal A. Aspirin intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation. Eur Respir J 1989; 2: 127-129.
74. Szczeklik A. The cyclo-oxygenase theory of aspirin-induced asthma. Eur Respir J 1990; 3: 588-593.
75. Mullins MD, Murray JJ, Serafin WE. Severe bronchospasm: when aspirin's the cause. Drug Therapy 1994; June: 20-28.
76. Stevenson DD, Simon RA. Sensitivity to aspirin and non-steroidal anti-inflammatory drugs. In: Allergy: Principles and Practice. 4th Edition. St Louis, Mo: CV Mosby, 1993; 1747-1765.
77. Manning ME, Stevenson DD. Aspirin sensitivity. A distressing reaction that is now often treatable. Postgrad Med 1991; 90: 227-233.
78. FitzGerald GA. Dipyridamole. N Engl J Med 1987; 316: 1247-1257.
79. Oczkowski WJ, Turpie AG. Antithrombotic treatment of cerebrovascular disease. Baillières Clin Haematol 1990; 3: 781-813.
80. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995; 49: 856-884.
81. Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrick K. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 1995; 130: 877-892.
82. Frezzato M, Ruggeri M, Castaman G, Rodeghiero F. Polycythemia vera and essential thrombocythemia in young patients. Haematologica 1993; 78: 11-17.
83. Najean Y, Dresch C, Rain JD. The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. Br J Haematol 1994; 86: 233-235.
84. Messinezy M, Pearson TC. Incidence of myelofibrosis following treatment of primary polycythaemia by venesection. Br J Haematol 1995; 89: 228-230.
85. Barbui T, Finazzi G, Pearson TC. The management of essential thrombocythaemia. Hematology 1997; 2: 91-100.
86. DiMinno G, Silver MJ, Cerbone AM, Murphy S. Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 1986; 68: 886-891.